Learn More
7590 Background: Progression-free survival (PFS) in EGFR-mutant NSCLC p treated with erlotinib is unpredictable at the individual level. The initial presence of double mutations (EGFR L858R or del 19(More)
e21025 Background: Genetic diversity in lung cancer according to histological subtype has not been fully explored. BRCA1 and RAP80 influence response to chemotherapy. Musashi 2 activates HES-1 in the(More)
  • 1